BioMarin Reports Q3 2026 Revenue Growth Driven by Amicus Therapeutics Acquisition
BioMarin (BMRN) reported third-quarter revenues of $1.025 billion, marking a 32% year-over-year increase. This growth was primarily fueled by the acquisition of Amicus Therapeutics and strong demand for metabolic therapies, specifically Galafold and the combined Pombility/Opfolda portfolio. While VOXZOGO revenue grew 12%, Naglazyme saw an 11% decline due to order timing shifts. The company reported a GAAP net loss of $123 million, widening from $31 million in the prior year, largely due to acquisition-related amortization and interest expenses. Despite these costs, non-GAAP income rose to $45 million. BioMarin slightly adjusted its full-year revenue guidance to a range of $3.8 billion to $3.9 billion following an international order deferral.
Topics: acquisition impact financial guidance metabolic therapies revenue growth